

31st July, 2017

~~The Dy. General Manager (Listing Dept.)
BSE Limited.,
Corporate Relationship Dept.,
1st Floor, New Trading Ring,
P. J. Towers, Dalal Street, Fort,
Mumbai - 400 001
(BSE Scrip Code: 500420)~~

✓ The Manager – Listing Dept.,
National Stock Exchange of India Ltd.,
Exchange Plaza, 5th Floor,
Plot No. C/1, G. Block,
Bandra - Kurla Complex, Bandra (E),
Mumbai – 400 051
(NSE Scrip Code: TORNTPHARM)

Dear Sir,

Sub.: Intimation under Regulation 30 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements), 2015, (“Listing Regulations”) of:

- 1. Change in Auditor of the Company**
- 2. Re-appointment of Dr. Chaitanya Dutt, Director (Research & Development) as a whole time director**

As per Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015, we hereby inform that members in their meeting dated 31st July, 2017 considered and approved the following:


1. Appointment of B S R & Co. LLP, Chartered Accountants (Firm Registration No. 101248W/W-100022), as Statutory Auditors of the Company to hold the office from the conclusion of the 44th Annual General Meeting until the conclusion of the 49th Annual General Meeting, subject to ratification by members every year, at such remuneration, as may be decided by the Board of Directors of the Company.
2. Re-appointment of Dr. Chaitanya Dutt, Director (Research & Development) as a whole-time director for a period of 3 years commencing from 1st January, 2018

The above is for your information and record.

Thanking you,

Yours Sincerely,

For TORRENT PHARMACEUTICALS LIMITED



MAHESH AGRAWAL
MVP (LEGAL) & COMPANY SECRETARY